title: The effect of low-dose pravastatin in metabolic syndrome for primary prevention of cardiovascular disease in Japan: a post hoc analysis of the MEGA study.
abstract: The Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study demonstrated the beneficial effect of low-dose pravastatin treatment (10-20 mg/d) on cardiovascular disease (CVD) in Japanese patients with mild-to-moderate hypercholesterolemia. However, it is not known whether mild lipid modification is effective even for patients at high risk. In this study, we evaluated low-dose pravastatin treatment in patients with metabolic syndrome in the MEGA Study. Metabolic syndrome (MetSyn) was defined according to the modified US National Cholesterol Education Program criteria. There were 72 coronary heart disease (CHD) events and 130 CVD events in 2636 patients with MetSyn, and 70 CHD events and 125 CVD events in 5196 patients without MetSyn (hazard ratios 1.85 and 1.90, respectively). No significant risk reduction in CHD was found in the diet plus pravastatin group compared with the diet group patients with MetSyn (hazard ratio .78, P = .29). On the other hand, there was a significant 36% CVD risk reduction (P = .01) in the diet plus pravastatin group compared with the diet group patients with MetSyn, with a small number needed to treat (45). These results indicate that low-dose pravastatin provides a substantial beneficial effect for the prevention of CVD in Japanese patients with MetSyn without known CVD, a population at proportionally high risk in primary prevention.
authors.affiliation: Faculty of Human Life Science, Jissen Women's University, Tokyo, Japan. matshima@nifty.com
authors.forename: Teruhiko
authors.initials: T
authors.lastname: Matsushima
authors.forename: Noriaki
authors.initials: N
authors.lastname: Nakaya
authors.forename: Kyoichi
authors.initials: K
authors.lastname: Mizuno
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Ohashi
authors.forename: Tamio
authors.initials: T
authors.lastname: Teramoto
authors.forename: Shinji
authors.initials: S
authors.lastname: Yokoyama
authors.forename: Shuichi
authors.initials: S
authors.lastname: Ichikawa
authors.forename: Norio
authors.initials: N
authors.lastname: Ishikura
authors.forename: Kimihide
authors.initials: K
authors.lastname: Kamiyama
authors.forename: Haruo
authors.initials: H
authors.lastname: Nakamura
mesh_terms: D000328:Adult; D000368:Aged; D000924:Anticholesteremic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control*; D003131:Combined Modality Therapy; D003327:Coronary Disease / Q000209:etiology / Q000517:prevention & control; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007564:Japan; D008297:Male; D024821:Metabolic Syndrome / Q000150:complications / Q000178:diet therapy / Q000188:drug therapy*; D008875:Middle Aged; D017035:Pravastatin / Q000008:administration & dosage / Q000494:pharmacology*; D011322:Primary Prevention / Q000379:methods
chemical_list: D000924:Anticholesteremic Agents; D017035:Pravastatin